What is one of the drugs included in the ABVD treatment regimen for Hodgkin's lymphoma?

The ABVD treatment regimen for Hodgkin's lymphoma consists of four specific chemotherapy drugs: Adriamycin (doxorubicin), Bleomycin, Vinblastine, and Dacarbazine. Bleomycin is one of the key components of this regimen and plays a crucial role in its efficacy.

Bleomycin works by inducing DNA strand breaks, which ultimately leads to apoptosis (programmed cell death) in cancer cells. Its inclusion in the ABVD regimen is significant because it targets the rapidly dividing cells characteristic of Hodgkin's lymphoma and contributes to the overall success of the treatment in achieving remission.

In contrast, the other drugs mentioned—Cisplatin, Dexamethasone, and Paclitaxel—are not part of the standard ABVD regimen for Hodgkin's lymphoma. Cisplatin is often used in the treatment of various solid tumors, Dexamethasone is a corticosteroid used to reduce inflammation and suppress the immune system, and Paclitaxel is primarily utilized in cases of breast, lung, and ovarian cancers. Their absence from the ABVD regimen underscores the specific and targeted approach of ABVD for treating Hodgkin's lymphoma.